Moderna (MRNA) Stock Surges Following Historic $950M Patent Settlement

Key Takeaways

Table of Contents

Moderna has committed to a $950 million immediate payment to Arbutus Biopharma and Genevant Sciences, ending patent litigation regarding COVID vaccine technology.
An additional $1.3 billion payment may be required if Moderna’s ongoing federal appeal is unsuccessful.
This agreement represents the pharmaceutical industry’s largest recorded patent settlement and ranks second across all sectors.
Following the settlement announcement, Moderna shares surged 8.7% to $54.15 in after-hours trading.
The company projects cash reserves between $4.5–$5 billion by the close of 2026, with overall liquidity reaching $5.9 billion.

Moderna has brought closure to a protracted patent dispute — and investors responded enthusiastically.

On Tuesday evening, the biotech giant revealed plans to deliver a $950 million upfront payment to Arbutus Biopharma (ABUS) and private entity Genevant Sciences, effectively ending worldwide patent litigation concerning its Spikevax and mResvia vaccine products.

At the heart of the controversy was lipid nanoparticle (LNP) delivery technology, a crucial component for delivering mRNA into cells. Arbutus and Genevant had filed lawsuits against Moderna, alleging unauthorized use of their proprietary LNP technology.

Arbutus stock declined 11% to $4.20 during after-hours trading following the announcement.

The $950 million settlement will be reflected as an expense in Q1 2026, with the full amount disbursed in Q3. Following this payment, Moderna will have no ongoing royalty obligations.

However, one condition remains. Moderna has filed an appeal with a federal circuit court, asserting limited liability based on its status as a government contractor. Should this appeal fail, the company has committed to paying an additional $1.3 billion within a 90-day window.

The combined potential liability of $2.25 billion remains significantly lower than initial projections. William Blair analysts highlighted that market participants had anticipated closer to $5 billion in total exposure, which could have created substantial liquidity challenges.

Under the agreement’s terms, Genevant is providing Moderna with a worldwide non-exclusive license for its LNP delivery platform for specific mRNA vaccine applications. Genevant has also committed to refraining from future patent litigation against Moderna for designated intellectual property.

Impact on Moderna’s Financial Standing

Factoring in the settlement terms, Moderna anticipates closing 2026 with cash and equivalents ranging from $4.5 billion to $5 billion. The company maintains access to an existing $900 million credit line, positioning total anticipated liquidity between $5.4 billion and $5.9 billion.

CEO Stéphane Bancel emphasized that the agreement eliminates uncertainty, allowing the organization to concentrate on future objectives.

Bancel projects Moderna will achieve revenue growth by late 2026. The company aims to secure regulatory approval for its combined flu-COVID vaccine alongside a standalone influenza vaccine within the current year.

Future Pipeline and Clinical Data Expected

Multiple clinical trial readouts in oncology and rare disease programs are anticipated throughout 2026, which William Blair analysts identified as possible “new long-term growth drivers.”

The settlement eliminates what had become a persistent concern weighing on investor sentiment. Moderna’s mRNA technology platform forms the foundation of its extensive development pipeline extending beyond COVID-19 applications.

Both Arbutus and Genevant characterized the agreement as the pharmaceutical industry’s largest publicly disclosed patent settlement and the second-largest recorded across all industries.

Genevant CEO James Heyes described the outcome as “enormously gratifying,” acknowledging recognition for the firm’s role in addressing the pandemic.

Moderna shares have appreciated more than 60% throughout the past year, substantially outperforming the S&P 500’s approximately 17% increase during the same timeframe.

The $950 million lump-sum payment is scheduled for Q3 2026.

✨ Limited Time Offer